Cheyenne, WY / Bracknell, Berkshire, UK (PRWEB) April 18, 2012
A year ago AIMM Therapeutics, a Netherlands based Biotech company, that develops high quality human monoclonal antibodies to treat disease using its proprietary technologies AIMSelect™, AIMProve™ and AIMLink™, bought the PatentSafe electronic lab notebook system (ELN) to increase efficiency and promote collaboration. Twelve months later they have achieved these goals and are seeing additional benefits.
Looking to eliminate time spent on cutting and sticking data into paper based lab notebooks and make it easier to share experimental results and protocols, AIMM Therapeutics moved over to the Electronic Lab Notebook following a successful pilot of the PatentSafe system. Now the system has been in use for a while and other useful consequences are becoming apparent. Rob Swan, Global Business Development Manager at Amphora explains, “A company will usually buy PatentSafe because they have a specific need that they are looking to fill, a specific pain as it were. Once they have been using the system for a while though, it is all the unexpected things that make them enthusiastic advocates of the system.”
Dr Tim Beaumont, Managing and Senior Scientist at AIMM explained “We have seen an improvement in the quality of experiment write ups, people are standardising their protocols and making things clearer, which makes everyone’s life easier.” He went on to add “If I am preparing a presentation, I can go to PatentSafe and pull the data I need to demonstrate a point in one clear graph, and I can do it securely from home.”
PatentSafe is a direct replacement for the bound laboratory notebook. Completely discipline neutral it allows scientists to gain the benefits of electronic working methods without having to experience the upheaval of major changes in working practices. Amphora's PatentSafe solution delivers significant ROI with little disruption and at a price that can work for organisations of all sizes and types.
Notes for Editors
Amphora Research Systems has been releasing scientists from the tyranny of the Paper Laboratory Notebook since 1996. Its software products, including PatentSafe, are used around the world by large and small companies, including those in the pharmaceutical and chemical sectors. PatentSafe helps scientists to work better, collaborate easily with each other, and protect their inventions.
AIMM is a “spin-out” of the Netherlands Cancer Institute and the Academic Medical Center at the University of Amsterdam that develops high quality human monoclonal antibodies to treat diseases with a high, unmet medical need. AIMM exploits the proprietary technologies AIMSelect™, AIMProve™ and AIMLink™ to generate stable monoclonal cell lines of human antibody-producing B cells against infectious agents.